On June 17, 2025, Needham analyst Mike Matson reaffirmed a "Hold" rating for TransMedics Group (TMDX, Financial). This decision marks a continuation of the previously set rating. The evaluation by Needham comes without any changes to the price target, as none was provided in the latest assessment.
The stock, identified by the ticker (TMDX, Financial), remains under close watch by investors following this update. As of now, no new price target or percentage change has been indicated, reflecting a steady outlook from the Needham team.
TransMedics Group (TMDX, Financial) will continue to attract attention in the market as stakeholders await further insights on its performance and any potential future updates from Needham or other analysts. For now, the "Hold" rating suggests a neutral stance towards the stock.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 8 analysts, the average target price for TransMedics Group Inc (TMDX, Financial) is $136.50 with a high estimate of $179.00 and a low estimate of $103.00. The average target implies an downside of 3.85% from the current price of $141.96. More detailed estimate data can be found on the TransMedics Group Inc (TMDX) Forecast page.
Based on the consensus recommendation from 10 brokerage firms, TransMedics Group Inc's (TMDX, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for TransMedics Group Inc (TMDX, Financial) in one year is $252.18, suggesting a upside of 77.64% from the current price of $141.96. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the TransMedics Group Inc (TMDX) Summary page.
